P-COMM-B Induction Chemotherapy in Intermediate and High Grade Non-Hodgkins Lymphoma

References

• Coltman C. A., Dahlberg S., Jones S. E. CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve year South West Oncology Group (SWOG) follow-up. Advances in cancer chemotherapy. Update on treatment for diffuse large cell lymphoma, AT Skarin. Wiley, New York 1986; P71–82
   Google Scholar
• Jones S. E., Grozea P. N., Miller T. P., Van Slyck E. J., Balcerzak S. P., Costanzi J. J., Morrison F. S., Eyre H. J., Fabian C. J., Dabich L., Dixon D. O., Hartsock R. J., Grogan T. M., Kjeldsberg C., Schnitzer B. Chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group study. Journal of Clinical Oncology 1985; 3(10)1318–1324
   PubMed Web of Science ®Google Scholar
• McKelvey E. M., Gottlieb J. A., Wilson H. E. Hydroxyldaunorubicin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Armitage J. O. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma. Annals of Oncology 1991; 2: 37–41, (Suppl 1)
   PubMed Web of Science ®Google Scholar
• Klimo J. M., Connors P. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Seminars in Hematology 1987; 25(2)41–46
   Web of Science ®Google Scholar
• Goldie J. H., Coldman A. J. A mathematical model for relating the drug sensitivity of tumours to the spontaneous mutation rate. Cancer Treatment Reports 1979; 63: 1727–1733
   PubMedGoogle Scholar
• Connors J. M., Klimo P. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Seminars in Hematology 1988; 25: 41–46, 2 suppl 2
   PubMed Web of Science ®Google Scholar
• Gams R. A., Steinberg J., Posner L. Mitoxantrone in malignant lymphoma. Seminars in Oncology 1984; 11(1)3, 47–49
   Google Scholar
• Non-Hodgkins Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of clasifications of non-Hodgkins lymphoma: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Zubrod C. G., Scheiderman M., Frei E. Cancer—appraisal of methods for the study of chemotherapy of cancer in man: Hiophosphoramide. Journal of Chronic Diseases 1960; 11: 7–33
   Google Scholar
• Kaplan E. L., Meier P. Non-parametric estimation from incomplete observations. Journal of the American Statistics Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• World Health Organization. Handbook for reporting results of cancer treatment. WHO Offset Publication no. 48. Den Haag, Nijhoff 1979
   Google Scholar
• Schneider A. M., Straus D. J., Schluger A. E., Lowenthal D. A., Koziner B., Lee B. J., Wong G., Clarkson B. D. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkins lymphomas. Journal of Clinical Oncology 1990; 8: 94–102
   PubMed Web of Science ®Google Scholar
• Wieck J. K., Dahlberg S., Fisher R. I., Dana B., Miller T. P., Balcerzak S. P., Pierce H. I. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkins lymphoma with MACOP-B: a Southwest Oncology Group study. Journal of Clinical Oncology 1991; 9: 748–753
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. The New England Journal of Medicine 1993; 328: 1002–6
   PubMed Web of Science ®Google Scholar
• Hall T. C., Choi O.S., Abadi A., Krant M.J. High dose corticoid therapy in Hodgkins disease and other lymphomas. Annals of Internal Medicine 1967; 66(6)1144–1153
   PubMed Web of Science ®Google Scholar
• Doroshaw J. H., Locker G. Y., Gaasterland D. E., Hubbard S. P., Young R. C., Myers C. E. Ocular irritation from high dose methotrexate therapy: pharmacokinetics of drug in the tear film. Cancer 1981; 48: 2158–2162
   PubMed Web of Science ®Google Scholar
• State F. A., Hamed M. S., Bondok A. A. Effect of vincristine on the histological structure of taste buds. Acta Anatomica 1977; 99: 445–449
   PubMedGoogle Scholar
• Mazza P., Bocchia M., Zanchini R., Gherlinzoni F., Zinzani P. L., Pileri S., Tura S. MN (N = Novantrone) COP-B therapy on high and intermediate grade non-Hodgkins lymphoma: an alternative to MA (A = adriamycin) COP-B?. Hematologica 1991; 76(1)47–52
   PubMedGoogle Scholar
• Brusamolino E., Bertini M., Guidi S., Vitolo U., Inverardi D., Meranti S., Colombo A., Resegotti L., Bemasconi C., Ferrini P., Cametti G., Canta M. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkins lymphoma: an interim report comparing efficacy and toxicity. Hematologica 1988; 73: 217–222
   PubMed Web of Science ®Google Scholar
• Pavlovsky S., Santorelli M. T., Erazo A., Diaz Maqueo J. C., Somoza N., Lluesma Gonalons M., Cervantes G., Garcia Vela E. L., Corrado C., Magnasco H., Milone G. Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. Annals of Oncology 1992; 3(3)205–9
   PubMed Web of Science ®Google Scholar
• Gherlinzoni F., Guglielmi C., Mazza P., Amadori S., Mandelli F., Tura S. Phase III comparative trial (M-BACOD v M-BNCOD) in the treatment of stage II to IV non-Hodgkins lymphomas with intermediate or high grade histology. Seminars in Oncology 1990; 17: 3–9, (Suppl 10)
   PubMed Web of Science ®Google Scholar
• Guglielmi C., Gherlizoni F., Amadori S., Mazza P., Mantovani L., Lauria F., Martelli M., Zinzani P. L., Greco V., Polletti G., Gherardi S., Mandelli F., Tura S. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II–IV diffuse non-Hodgkins lymphomas. Hematologica 1989; 74(6)563–569
   PubMedGoogle Scholar